Technologies to rapidly find inhibitors for carbohydrate-binding proteins in heart disease
Official title: Technologies for Directed Evolution of Glycoaptamers
Funded at Brandeis University · NIH-11389245 · Data updated 2026-11-12
A Brandeis-led project will develop new tools to quickly find inhibitors of carbohydrate-binding proteins that play a role in atherosclerotic cardiovascular disease, using advanced RNA-based aptamers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $319,150 |
| NIH project number | 5R01GM151492-04 |
| Project ID | NIH-11389245 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with ASCVD who may benefit from novel therapies targeting CBP pathways in research contexts or future trials.
✕Less likely to help
People with ASCVD not involved in related investigative efforts or without access to future inhibitor-based treatments may not directly benefit.
What this research studies
If you have a condition like atherosclerotic cardiovascular disease, this project aims to create faster methods to identify molecules that block specific protein-glycan interactions involved in disease processes. Researchers will engineer special RNA aptamers that display sugars in ways that CBPs recognize, and also create simpler single-glycan aptamers to guide binding. The work is focused on making these inhibitors work in living systems by improving affinity and specificity. The outcome could lead to new ways to modulate inflammation, vessel health, and tissue remodeling linked to ASCVD.
Why it matters
Potential benefit: If successful, this technology could enable faster development of targeted therapies to prevent or reduce atherosclerotic disease progression.
How similar studies have gone: Previous work shows CBP inhibitors can influence disease-related processes; this project builds on that by accelerating discovery with new aptamer technologies.
Where this research is happening
-
Brandeis University
Waltham, United States Active
Researchers
- Principal investigator: Krauss, Isaac Jonathan — Brandeis University
- Study coordinator: Krauss, Isaac Jonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.